Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Federica Brescia"'
Autor:
Michela Spadaro, Serena Martire, Luca Marozio, Daniela Mastromauro, Elena Montanari, Simona Perga, Francesca Montarolo, Federica Brescia, Alessia Balbo, Giovanni Botta, Chiara Benedetto, Antonio Bertolotto
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Pregnancy is a naturally occurring disease modifier of multiple sclerosis (MS) associated with a substantial reduction in relapse rate. To date, attempts to explain this phenomenon have focused on systemic maternal immune cell composition, with contr
Externí odkaz:
https://doaj.org/article/ebd66f10fab24a02862398e79254f853
Autor:
Federica Brescia, Luca Ronconi
Publikováno v:
Future Medicinal Chemistry. 15:647-650
Plain language summary From jewels and coinage to anticancer and antiviral agents, the peculiar ‘soft’ character as well as physicochemical, redox and ligand exchange properties of gold can be exploited to design novel bioactive complexes, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3145e0df2fbc4807f43c0f7201da417
https://doi.org/10.4155/fmc-2023-0078
https://doi.org/10.4155/fmc-2023-0078
Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod
Autor:
Federica Brescia, M. Lo Re, Serena Martire, Antonio Bertolotto, Marzia Caldano, Simona Perga, Francesca Montarolo, Giancarlo Panzica
Background and purpose Fingolimod is a drug approved for treatment of relapsing-remitting multiple sclerosis (RRMS) that exerts its effects via sequestering lymphocytes within the lymph nodes. The drug, acting on the sphingosine-1-phosphate pathway,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd361727f80980b012243ca72bf6272
http://hdl.handle.net/2318/1694580
http://hdl.handle.net/2318/1694580
Autor:
Michela Spadaro, Serena Martire, Antonio Bertolotto, Federica Brescia, Simona Perga, Francesca Montarolo, Simona Malucchi
Publikováno v:
Clinical immunology (Orlando, Fla.). 181
Glatiramer acetate (GA) is a widely used treatment for multiple sclerosis (MS), with incompletely defined mechanism of action. Short-term studies suggested its involvement in the modulation of anti-inflammatory cytokines and regulatory T cells (Treg)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1f0c556a17942bada3b16f8bfcc1c6
https://pubmed.ncbi.nlm.nih.gov/28642148
https://pubmed.ncbi.nlm.nih.gov/28642148